Background Gliosarcoma is a rare variant of IDH- wild type glioblastoma with both glial and mesenchymal differentiation. It accounts for approximately 2% of glioblastomas and has a poor prognosis similar to that of classic glioblastoma. It is seen mostly between 40 and 60 years of age with a mean age over 50 years. Pediatric gliosarcoma is even rarer than gliosarcoma in adults. We describe the clinicopathological features of gliosarcoma in patients under 20 years of age and determine whether there are significant differences from gliosarcoma in adults. We also present detailed review of published literature on pediatric gliosarcoma. Methods Slides of gliosarcomas in patients under 20 years of age were reviewed. Clinicopathological features were noted in detail and follow up was obtained. Results Eleven cases of gliosarcoma were reported in patients under 20 years of age. Ages ranged from three to 19 years (mean age 13 years). Frontal, parietal and temporal lobes were the commonest locations. Mean and median tumor size was six and five cm respectively. All 11 cases demonstrated the classic biphasic pattern. In 10 cases, glial component was astrocytic and was highlighted on GFAP. Sarcomatous component in most cases resembled fibrosarcoma and was high grade in 72.7%. Glial areas were reticulin poor while sarcomatous areas were reticulin rich. In over 45% cases, bizarre tumor giant cells were seen in the sarcomatous areas. In 1 case, sarcomatous areas showed extensive bone and cartilage formation. Other histologic features included hyalinized blood vessels, hemorrhage, infarction, gemistocytic cells, rhabdoid cells etc. Follow up was available in nine patients, five received chemoradiation post resection while three received radiotherapy only. Prognosis was dismal and eight patients died within one to 14 months following resection. Conclusions Gliosarcomas in patients under 20 comprised 13% of all gliosarcomas reported during the study period. Frequency and mean age were higher compared to other published reports. Pathological features were similar to those described in literature. Clinicopathological features and prognosis of pediatric gliosarcomas were similar to adult gliosarcomas.
Fluoride ions (F-) from natural sources or industrial wastewater are the main cause of many pathological conditions in people living in more than 25 countries. Thus, removing F- from drinking water is pivotal for preventing serious health consequences. The WHO recommends a limit of 1,5 mg/L for fluoride in drinking. Excessive amounts of fluoride in drinking water are prevalent in Pakistan, leading to related health risks. Low-cost techniques for the defluoridation of drinking water can be used. In this study, the removal of fluoride from drinking water by an adsorption method using low-cost materials/adsorbents, such as marble chips, wheat husks, rice husks, egg shells, concrete, fuller earth, fly ash, freshly fired bricks, and charcoal, at different contact times and different bed thicknesses were investigated. A batch sampling technique was used for sample collection. On average, marble chips, wheat husks, rice husks, egg shells, concrete, fuller earth, fly ash, freshly fired bricks, and activated charcoal (rice husk) resulted in 71,99 %; 90,99 %; 66,73 %; 90,99 %; 63,30 %; 71,99 %; 22,60 %; 49,67 %; and 90,13 % fluoride removal, respectively. Therefore, defluoridation using these materials is desirable. The performance of adsorbents depends on parameters such as contact time, depth of the adsorbent media, and pH. The bed thickness of the adsorbent has a minor effect on fluoride removal. The major contributors to fluoride removal from water are contact time and adsorbent composition.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.